TY - JOUR
T1 - Optimising PrEP Uptake and Use in Peru: No Time to Lose!
AU - Menacho, Luis
AU - Konda, Kelika A.
AU - Lecca, Leonid
AU - Cabello, Robinson
AU - Lankowski, Alexander
AU - Benites, Carlos
AU - Gallardo-Cartagena, Jorge A.
AU - Duerr, Ann
AU - Sánchez, Jorge
AU - Galea, Jerome T.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - In May, 2010, results of the multicountry iPrEx study were released: daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate effectively prevented HIV infection among men who have sex with men (MSM) and transgender women.1 The new intervention, pre-exposure prophylaxis (PrEP), was approved by the US Food and Drug Administration in 2012, and a broad global scale-up was anticipated. In Peru, where more than half of all iPrEx participants were enrolled, PrEP was urgently needed, and in 2016 its use was approved by the Ministry of Health; however, access was limited to demonstration studies (that began in 2017) or unsubsidised private sector purchases, and uptake was poor. By mid-2023, according to UNAIDS data, less than 3000 people had initiated PrEP, and in September, 2023, only about 0·9% (approximately 800 people) of the estimated 90 000 who could benefit from PrEP, were receiving it.2 Meanwhile, new HIV infections among adults (aged ≥15 years) in Peru have increased by 52% since 2012.
AB - In May, 2010, results of the multicountry iPrEx study were released: daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate effectively prevented HIV infection among men who have sex with men (MSM) and transgender women.1 The new intervention, pre-exposure prophylaxis (PrEP), was approved by the US Food and Drug Administration in 2012, and a broad global scale-up was anticipated. In Peru, where more than half of all iPrEx participants were enrolled, PrEP was urgently needed, and in 2016 its use was approved by the Ministry of Health; however, access was limited to demonstration studies (that began in 2017) or unsubsidised private sector purchases, and uptake was poor. By mid-2023, according to UNAIDS data, less than 3000 people had initiated PrEP, and in September, 2023, only about 0·9% (approximately 800 people) of the estimated 90 000 who could benefit from PrEP, were receiving it.2 Meanwhile, new HIV infections among adults (aged ≥15 years) in Peru have increased by 52% since 2012.
U2 - 10.1016/S2352-3018(24)00038-9
DO - 10.1016/S2352-3018(24)00038-9
M3 - Article
VL - 11
SP - e204-e206
JO - The Lancet HIV
JF - The Lancet HIV
IS - 4
ER -